Staquis Adverse Reactions

The most common adverse drug reactions from completed STAQUIS clinical trials (Trials 1 and 2) were application site reactions (5.6% and 3.6% for STAQUIS and vehicle groups, respectively) and most were classified as mild. Of these drug-related application site reactions, application site pain (e.g., burning or stinging) was the only adverse drug reaction that showed a clinically relevant difference in rates between the treatment groups (4.4% and 1.2% for STAQUIS and vehicle groups, respectively). Generally, application site pain was noted early in the treatment period and was transient in nature, resolving spontaneously. (See Table 5.)

Click on icon to see table/diagram/image

In Trial 3 the adverse drug reactions observed during the twice daily treatment open label period for up to 8 weeks were consistent with the known safety profile of twice daily STAQUIS. During the double-blind maintenance period in Trial 3 through Week 52, no cases of application site pain in the once daily STAQUIS-treated group were reported compared to 1.5% (2/135 subjects) in the once daily vehicle-treated group (see Pharmacology: Pharmacodynamics under Actions).
Pediatric clinical trial: In a multicenter, open-label, uncontrolled trial, 137 pediatric subjects aged 3 months to less than 2 years were treated with STAQUIS twice daily for 4 weeks. Overall, the safety profile of STAQUIS in this age group was consistent with that of Trials 1 and 2 in subjects 2 years of age and older.